What is the preferred site for administering IM injections in toddlers aged 12 months to 2 years?

Asthma classification is based on the frequency of daytime symptoms and nocturnal awakenings. Knowledge of the National Asthma Education and Prevention Program guidelines is required to correctly categorize severity, which dictates the pharmacological "step" therapy for pediatric patients.

Choice A rationale

Daily symptoms with nighttime episodes occurring more than once a week characterize moderate persistent asthma. This level of severity requires a higher dose of inhaled corticosteroids and potentially long-acting beta-agonists to maintain adequate pulmonary function.

Choice B rationale

Mild persistent asthma is defined by symptoms occurring more than twice weekly but less than daily. Nighttime awakenings happen three to four times per month. This classification necessitates the daily use of a low-dose anti-inflammatory controller.

Choice C rationale

Symptoms less than twice a week and nighttime episodes less than twice a month define intermittent asthma. This category typically only requires a rescue inhaler, such as albuterol, for as-needed use during acute bronchospasm episodes.

Choice D rationale

Continual symptoms throughout the day and frequent nighttime awakenings are indicative of severe persistent asthma. This reflects significantly limited physical activity and requires high-intensity therapy to prevent life-threatening exacerbations and maintain airway patency.

Planning care for Duchenne muscular dystrophy involves applying knowledge of its progressive, X-linked recessive nature. Understanding the typical trajectory of muscle degeneration, including respiratory and cardiac involvement, is necessary to anticipate complications and provide appropriate multidisciplinary support.

Choice A rationale

Duchenne muscular dystrophy is a progressive, degenerative disease caused by the absence of dystrophin. It does not improve over time; instead, muscle weakness inevitably worsens as muscle fibers are gradually replaced by fat and connective tissue throughout the child's life.

Choice B rationale

Cognitive impairment in Duchenne muscular dystrophy is related to the absence of certain dystrophin isoforms in the brain. Unlike motor skills, these cognitive deficits are usually non-progressive, but they do not typically improve significantly through intensive physical or medical therapy.

Choice C rationale

Children with Duchenne muscular dystrophy may experience oropharyngeal muscle weakness and cognitive delays that affect speech. Planning must account for these communication barriers to ensure the child can express needs and participate in their care as the disease progresses.

Choice D rationale

Mobility concerns in Duchenne muscular dystrophy typically arise in early childhood, often between ages three and five. Most children require a wheelchair by age twelve. Mobility issues do not wait until adulthood but are a hallmark of early disease progression..